|
US3498989A
(en)
|
1969-04-16 |
1970-03-03 |
American Home Prod |
Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
|
|
US3870715A
(en)
|
1972-03-09 |
1975-03-11 |
Nikolaus R Hansl |
Substituted amino ethyl meta benzoic acid esters
|
|
US4041174A
(en)
|
1974-08-16 |
1977-08-09 |
Rom-Amer Pharmaceuticals, Ltd. |
Method of treating depression
|
|
US5204356A
(en)
|
1985-07-24 |
1993-04-20 |
Glaxo Group Limited |
Treatment of anxiety
|
|
US6150354A
(en)
|
1987-01-15 |
2000-11-21 |
Bonnie Davis |
Compounds for the treatment of Alzheimer's disease
|
|
GB8819494D0
(en)
|
1988-08-16 |
1988-09-21 |
Ucb Sa |
Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
|
|
JPH06502184A
(ja)
*
|
1991-02-22 |
1994-03-10 |
シャピロ，ハワード ケイ． |
神経性疾病の症候や原因上関係のある症候の治療のための薬用化合物の使用
|
|
US6746678B1
(en)
|
1991-02-22 |
2004-06-08 |
Howard K. Shapiro |
Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
|
|
FR2700117B1
(fr)
|
1993-01-07 |
1995-02-03 |
Rhone Poulenc Rorer Sa |
Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
|
|
DE4340273A1
(de)
|
1993-11-26 |
1995-06-01 |
Karla Dr Lehmann |
Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
|
|
US5453425A
(en)
|
1994-07-11 |
1995-09-26 |
Janssen Pharmaceutica N.V. |
Risperidone oral formulation
|
|
AU4517201A
(en)
|
1999-12-08 |
2001-06-18 |
Vanderbilt University |
Modulation of in vivo glutamine and glycine levels in the treatment of autism
|
|
NZ524554A
(en)
|
2000-08-14 |
2005-07-29 |
Teva Pharma |
Preparation of risperidone
|
|
US20030185754A1
(en)
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
|
BR0206495A
(pt)
|
2001-01-16 |
2006-01-24 |
Genset Sa |
Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
|
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
|
US20070053976A1
(en)
|
2002-05-17 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
Novel combination of drugs as antidepressant
|
|
US7053122B2
(en)
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
CN100339070C
(zh)
|
2002-10-24 |
2007-09-26 |
莫茨药物股份两合公司 |
包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
|
|
WO2004065348A1
(en)
|
2003-01-23 |
2004-08-05 |
Pfizer Products Inc. |
Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
|
|
JP2006526635A
(ja)
|
2003-06-02 |
2006-11-24 |
サマリタン，ファーマスーティカルス，インク． |
血清中コルチゾール量を調節する方法および組成物
|
|
CN101798291A
(zh)
|
2003-12-29 |
2010-08-11 |
塞普拉科公司 |
苯并[d]异噁唑-3-醇DAAO抑制剂
|
|
EP1709053B1
(en)
|
2004-01-27 |
2011-04-06 |
Synthon B.V. |
Stable salts of olanzapine
|
|
JP2007523165A
(ja)
|
2004-02-18 |
2007-08-16 |
セプレイコー インコーポレイテッド |
睡眠の質を改善するためのドーパミン作動薬併用療法
|
|
EP1742535A4
(en)
|
2004-05-06 |
2008-10-15 |
Cydex Pharmaceuticals Inc |
MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
|
|
JP5017103B2
(ja)
|
2004-06-17 |
2012-09-05 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
薬剤共結晶組成物および関連した使用方法
|
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
|
CA2505808A1
(en)
*
|
2005-05-02 |
2006-11-02 |
Julie Danielle Globus |
Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
|
|
WO2006129160A2
(en)
|
2005-06-01 |
2006-12-07 |
Aurobindo Pharma Limited |
Stable aqueous oral solution of risperidone
|
|
US20110045065A1
(en)
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
US7811604B1
(en)
|
2005-11-14 |
2010-10-12 |
Barr Laboratories, Inc. |
Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
|
|
GB0603181D0
(en)
|
2006-02-17 |
2006-03-29 |
Merck Sharp & Dohme |
Treatment of neurodegenerative and psychiatric diseases
|
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
|
WO2008034087A2
(en)
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Treating schizophrenia with combinations of levodopa and an antipsychotic agent
|
|
US8071143B2
(en)
*
|
2008-04-02 |
2011-12-06 |
Brandeis University |
Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
|
|
US20130338199A1
(en)
*
|
2008-07-11 |
2013-12-19 |
Uday Saxena |
Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
|
|
EP2310004A1
(en)
*
|
2008-07-11 |
2011-04-20 |
Kareus Therapeutics SA |
Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
|
|
GB0813709D0
(en)
*
|
2008-07-26 |
2008-09-03 |
Univ Dundee |
Method and product
|
|
JP2010106001A
(ja)
*
|
2008-10-31 |
2010-05-13 |
Theravalues Corp |
Ｐｐａｒ活性化剤
|
|
AU2010206886B2
(en)
|
2009-01-20 |
2016-05-05 |
Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center |
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
|
|
LT3656765T
(lt)
*
|
2010-07-23 |
2021-06-10 |
Grünenthal GmbH |
3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio druskos arba bendri kristalai
|
|
CA2831086A1
(en)
*
|
2011-03-24 |
2012-09-27 |
University Of South Florida |
Lithium compositions
|
|
US9035044B2
(en)
*
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
US9120766B2
(en)
*
|
2011-10-21 |
2015-09-01 |
Amri Ssci, Llc |
Methods of making cocrystals
|
|
LT2986618T
(lt)
|
2013-04-19 |
2022-04-11 |
University Of South Florida |
Organinio anijono ličio joniniai kokristaliniai junginiai ir kompozicijos
|
|
WO2014178040A1
(en)
|
2013-04-29 |
2014-11-06 |
Mapi Pharma Ltd. |
Co-crystals of dapagliflozin
|
|
WO2015086843A2
(en)
*
|
2013-12-13 |
2015-06-18 |
Conaris Research Institute Ag |
A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
|
|
JP2016517866A
(ja)
*
|
2014-03-24 |
2016-06-20 |
カオシュン・チャン・グン・メモリアル・ホスピタル |
認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用
|
|
CN103992320A
(zh)
*
|
2014-05-26 |
2014-08-20 |
南京工业大学 |
一种混悬结晶制备药物共晶的方法
|
|
WO2016081365A1
(en)
*
|
2014-11-19 |
2016-05-26 |
Rush University Medical Center |
Compositions and methods for treating lysosomal disorders
|
|
RU2582962C1
(ru)
*
|
2014-12-23 |
2016-04-27 |
Ольга Алексеевна Громова |
Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
|
|
WO2017215593A1
(en)
|
2016-06-13 |
2017-12-21 |
Syneurx International (Taiwan) Corp. |
Co-crystals of sodium benzoate and uses thereof
|